Is Cemiplimab an imported drug or a domestic drug?

Cemiplimab (Cemiplimab) is a new immune checkpoint inhibitor jointly developed by Regeneron and Sanofi in the United States. It is a typical original biological agent. The drug has been approved in overseas markets for the treatment of a variety of malignant tumors, including cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC). However, the situation in the domestic market is different. As of now, the original drug of cimepilimab has not been officially approved for marketing in China, and no domestic pharmaceutical company has launched a generic version.

This means that for domestic patients, if they need to use cimipilimab, they can only obtain overseas original drugs through overseas channels or international medical service platforms. From the perspective of drug classification, if it is approved for marketing in China in the future, it will be classified as an "imported original drug" rather than a domestic drug. For many patients and clinicians, this information is critical because the source and type of drug directly affect price, reimbursement, and accessibility.

China has also been accelerating the development and approval of anti-PD-1 drugs in recent years. Some domestically produced PD-1 monoclonal antibodies have been widely used in tumor treatment on the market. However, as a PD-1 inhibitor developed abroad, cimepilimab currently has no domestic alternatives to choose from. Therefore, in clinical practice, if a doctor believes that a patient is suitable for using this drug, he usually needs to make a decision based on comprehensive factors such as the patient's willingness to go abroad for medical treatment, financial affordability, and drug channels.

Judging from the overall trend, as the introduction of international innovative drugs accelerates, it is more likely that cimepilimab will be approved for marketing in China in the future. Once successfully introduced, it will not only improve drug accessibility for patients, but may also further promote competition in the domestic drug market, thereby promoting the overall development pattern of immunotherapy drugs.

Reference materials:https://www.libtayohcp.com/